Biogen’s commitment to improving patients’ lives goes further than scientific research and development. We look well beyond the patient’s condition and see the whole person. We listen to and interact with patients, advocacy organisations and healthcare societies one-on-one in order to gain insights into unmet needs.

These insights help us go beyond the treatments we develop to support patients through best-in-class support programmes and provision of information. Biogen also provides advocacy organisations with charitable contributions and general donations to support our shared goal of helping patients manage the burden of their disease and improving patient outcomes.

Our expertise and commitment have produced the industry’s most robust multiple sclerosis (MS) franchise, helping to manage the disease from its earliest signs through its later stages. Our vision is to extend this leadership to transform the standard of care for haemophilia, to excel in discovery science and continue innovating at the intersection of science, medicine and economics to transform drug development to further improve the lives of patients.